GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets
Feb 06, 2026 17:45 HKT |  |
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis
Feb 06, 2026 14:17 HKT |  |
|
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States
Feb 05, 2026 05:00 HKT |  |
|
REMSleep Receives Medicare PDAC Coding Approval for Complete DeltaWave Product Portfolio
Jan 31, 2026 02:40 HKT |  |
|
A True Empowerer - AGFA HealthCare Radiates Imaging Innovation at ECR 2026
Jan 15, 2026 16:00 HKT | |
|
Avantor Appoints Gladys Wang as Vice President, Bioprocessing Commercial, Asia, Middle East & Africa
Dec 24, 2025 12:20 HKT |  |
|
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China
Dec 15, 2025 21:00 HKT |  |
|
Everest Medicines Unveils 2030 Strategy as Directors and Substantial Shareholder Buy Over HKD 38 Million of Shares
Dec 15, 2025 16:59 HKT | |
|
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
Dec 12, 2025 14:35 HKT | |
|
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China
Dec 11, 2025 20:00 HKT | |
|
Cloudbreak Pharma Soars 80%+ on Multiple Catalysts, Driving Value Re-Rating
Dec 11, 2025 08:20 HKT | |
|
Immortal Dragons Backs Etheros Pharmaceuticals: Targeting Aging-Related Disease with Breakthrough Catalytic Antioxidants
Dec 05, 2025 15:00 HKT |  |
|
OBI-902 has been granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma
Nov 17, 2025 20:00 HKT |  |
|
Bright China 2025: Airdoc PBM Vision Rehabilitation Device Clinical Research Data Release
Nov 11, 2025 09:22 HKT |  |
|
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China
Oct 30, 2025 20:00 HKT | |
|
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
Oct 30, 2025 16:48 HKT | |
|
CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis(R) and Beovu(R)
Oct 27, 2025 22:00 HKT | |
|
Owkin Launches K Pro: The First Agentic AI Co-Pilot for Biopharma Powered by Biological Reasoning Models
Oct 16, 2025 13:00 HKT |  |
|
Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
Oct 14, 2025 17:38 HKT | |
|
Kangji Medical and Knight Bidco Jointly Dispatch Scheme Document for Privatisation Proposal
Oct 13, 2025 10:14 HKT | |
|